Skip to main navigation Skip to search Skip to main content

In silico analysis: Fulleropyrrolidine derivatives against HIV-PR mutants and SARS-CoV-2 Mpro

Research output: Contribution to journalArticlepeer-review

Abstract

Approximately 37.9 million people living with HIV (PLWH) are at risk of severe consequences from COVID-19. Urgent development of tailored treatments for PLWH, who have historically been excluded from vaccine trials, is crucial. The present study introduces some modified fulleropyrrolidine derivatives with chalcogen atoms (O, S, or Se) and hydroxymethylcarbonyl (HMC) groups to target 11 single and double HIV-1 protease (HIV-PR) mutations and the main protease of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2 Mpro). The inhibitory activities of these derivatives are computationally examined through molecular docking, molecular dynamic simulations for 200 ns, and Lipinski's rule of five (RO5). Fourier-transform infrared spectroscopy spectra and thermodynamic properties are calculated and analyzed using Density Functional Theory B88-PW91 method. The results indicate that the suggested O-compounds obey three parameters of the RO5 and HMC forms hydrogen bonds with studied viral proteases. Compounds with O and S additives display a high binding affinity with negative binding energy values for HIV-PR mutations (A71V-I84V, V77I-I84V, and I84V-L90M) and SARS-CoV-2 Mpro. The compounds with S and Se additives shift to lower frequencies of the major vibrational bands.

Original languageEnglish
Article number20240002
JournalComputational and Mathematical Biophysics
Volume12
Issue number1
DOIs
StatePublished - 1 Jan 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • COVID-19
  • FTIR
  • fulleropyrrolidine
  • HIV-1 protease mutants
  • SARS-CoV-2 M inhibitors

Fingerprint

Dive into the research topics of 'In silico analysis: Fulleropyrrolidine derivatives against HIV-PR mutants and SARS-CoV-2 Mpro'. Together they form a unique fingerprint.

Cite this